A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Completed · Phase 3 · Has a placebo group

Conditions studied: Early Alzheimer's Disease

In brief

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.

Key facts

Study ID

NCT04777396

Run by

Novo Nordisk A/S

People needed

1840

Starts

2021-05-18

Expected to finish

2026-01-30

Last updated by the study team

2026-07-07

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent.
• MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.
• CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home \& hobbies, community affairs) Or CDR global score of 1.0
• RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85
• MMSE (Mini-Mental State Examination) greater than or equal to 22
• Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) Aβ1-42 or CSF Aβ1-42/Aβ1-40 .
• If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary.

You may not qualify if…

• Brain MRI (or CT) scan suggestive of clinically significant structural CNS disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts greater than 10 mm in diameter], prior macro-haemorrhage [greater than 1 cm\^3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus).
• Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than1 lacunar infarct and/or ARWMC (age-related white matter changes) greater than 2, (WM (white matter) greater than 20 mm) in the deep white matter and periventricular regions.
• Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
• Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits
• Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.

Where it is running

• Imaging Endpoints — Scottsdale, Arizona, United States
• Banner Sun Health Research Institute — Sun City, Arizona, United States
• Tucson Neuroscience Research — Tucson, Arizona, United States
• Advanced Research Center, Inc. — Anaheim, California, United States
• Fullerton Neurology and Headache Center — Fullerton, California, United States
• Pacific Research Network — Lemon Grove, California, United States
• Torrance Clin Res Inst, Inc. — Lomita, California, United States
• ASCLEPES Research Centers, — Long Beach, California, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• UCLA_Los Angeles — Los Angeles, California, United States
• Wr-Pri, Llc — Newport Beach, California, United States
• Well Care Medical Center — Panorama City, California, United States
• Cedars-Sinai Medical Center — Pasadena, California, United States
• Sharp Neurocog Res Ctr — San Diego, California, United States
• Syrentis Clinical Research — Santa Ana, California, United States
• Calfornia Neurosc Resrch Med — Sherman Oaks, California, United States
• Southern California Research LLC — Simi Valley, California, United States
• Mountain Neurological Research Center, Inc. — Basalt, Colorado, United States
• Denver Neurological Research — Denver, Colorado, United States
• Mile High Research Center — Denver, Colorado, United States
• Yale University — Fairfield, Connecticut, United States
• Topaz Clinical Research — Apopka, Florida, United States
• JEM Research Institute — Atlantis, Florida, United States
• Visionary Investigators Network — Aventura, Florida, United States
• Banner Alzheimer's Institute — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.